Harrow Health, Inc. (HROW)
USD 22.2
(-3.85%)
USD 22.2
(-3.85%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 10.86 Million USD | 66.14% |
| 2022 | 6.54 Million USD | 55.11% |
| 2021 | 4.21 Million USD | 6.44% |
| 2020 | 3.96 Million USD | 20.02% |
| 2019 | 3.3 Million USD | 79.99% |
| 2018 | 1.83 Million USD | -18.45% |
| 2017 | 2.24 Million USD | 22.16% |
| 2016 | 1.84 Million USD | 30.38% |
| 2015 | 1.41 Million USD | 278.82% |
| 2014 | 372.73 Thousand USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 10.81 Million USD | -0.52% |
| 2024 Q2 | 9.42 Million USD | -12.81% |
| 2023 Q3 | 8.92 Million USD | 4.31% |
| 2023 Q1 | 9.09 Million USD | 39.02% |
| 2023 FY | 10.86 Million USD | 66.14% |
| 2023 Q4 | 10.86 Million USD | 21.77% |
| 2023 Q2 | 8.55 Million USD | -5.92% |
| 2022 Q4 | 6.54 Million USD | 23.81% |
| 2022 FY | 6.54 Million USD | 55.11% |
| 2022 Q3 | 5.28 Million USD | 2.94% |
| 2022 Q1 | 4.39 Million USD | 4.24% |
| 2022 Q2 | 5.13 Million USD | 16.74% |
| 2021 Q1 | 4.49 Million USD | 13.48% |
| 2021 FY | 4.21 Million USD | 6.44% |
| 2021 Q2 | 3.9 Million USD | -13.19% |
| 2021 Q3 | 3.92 Million USD | 0.56% |
| 2021 Q4 | 4.21 Million USD | 7.44% |
| 2020 Q1 | 3.98 Million USD | 20.84% |
| 2020 FY | 3.96 Million USD | 20.02% |
| 2020 Q4 | 3.96 Million USD | -0.3% |
| 2020 Q3 | 3.97 Million USD | 3.46% |
| 2020 Q2 | 3.84 Million USD | -3.71% |
| 2019 FY | 3.3 Million USD | 79.99% |
| 2019 Q1 | 2.38 Million USD | 30.21% |
| 2019 Q2 | 2.65 Million USD | 11.06% |
| 2019 Q3 | 2.44 Million USD | -7.88% |
| 2019 Q4 | 3.3 Million USD | 35.12% |
| 2018 Q1 | 2.04 Million USD | -9.29% |
| 2018 Q3 | 2.52 Million USD | 13.9% |
| 2018 Q4 | 1.83 Million USD | -27.34% |
| 2018 FY | 1.83 Million USD | -18.45% |
| 2018 Q2 | 2.21 Million USD | 8.63% |
| 2017 Q2 | 1.83 Million USD | -10.37% |
| 2017 FY | 2.24 Million USD | 22.16% |
| 2017 Q4 | 2.24 Million USD | -5.27% |
| 2017 Q3 | 2.37 Million USD | 29.59% |
| 2017 Q1 | 2.04 Million USD | 11.03% |
| 2016 Q2 | 1.44 Million USD | 16.87% |
| 2016 FY | 1.84 Million USD | 30.38% |
| 2016 Q4 | 1.84 Million USD | -3.21% |
| 2016 Q3 | 1.9 Million USD | 31.99% |
| 2016 Q1 | 1.23 Million USD | -12.68% |
| 2015 Q1 | 711 Thousand USD | 90.75% |
| 2015 Q2 | 793 Thousand USD | 11.53% |
| 2015 Q3 | 1.27 Million USD | 60.53% |
| 2015 Q4 | 1.41 Million USD | 10.92% |
| 2015 FY | 1.41 Million USD | 278.82% |
| 2014 Q2 | 172.75 Thousand USD | 244.62% |
| 2014 Q3 | 351.2 Thousand USD | 103.3% |
| 2014 Q4 | 372.73 Thousand USD | 6.13% |
| 2014 FY | 372.73 Thousand USD | 0.0% |
| 2014 Q1 | 50.12 Thousand USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Journey Medical Corporation | 10.2 Million USD | -6.477% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 90.227% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | -60.541% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 89.586% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -89.494% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -89.494% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| Safety Shot Inc | 1.86 Million USD | -481.233% |
| Alpha Teknova, Inc. | 11.59 Million USD | 6.27% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | 66.389% |
| Bright Green Corporation | - USD | -Infinity% |
| Dynavax Technologies Corporation | 53.29 Million USD | 79.608% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 83.44% |
| Cosmos Health Inc. | 4.78 Million USD | -126.913% |
| PainReform Ltd. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -1242.008% |
| Embecta Corp. | 152.1 Million USD | 92.855% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | 6.697% |
| Procaps Group, S.A. | 96.83 Million USD | 88.778% |
| Theratechnologies Inc. | 6.06 Million USD | -79.146% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -299.669% |
| Biofrontera Inc. | 10.9 Million USD | 0.376% |
| DURECT Corporation | 2.21 Million USD | -389.725% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 85.961% |
| Cronos Group Inc. | 30.33 Million USD | 64.181% |
| OptiNose, Inc. | 8.05 Million USD | -34.96% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -1086699900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | -90.681% |
| Organogenesis Holdings Inc. | 28.25 Million USD | 61.537% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -305.923% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | -135.759% |
| Radius Health, Inc. | 278.64 Million USD | 96.1% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -225.041% |
| ProPhase Labs, Inc. | 3.84 Million USD | -182.921% |
| Phibro Animal Health Corporation | 265.91 Million USD | 95.913% |
| Procaps Group S.A. | 96.83 Million USD | 88.778% |
| Alvotech | 74.43 Million USD | 85.4% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 99.687% |
| Rockwell Medical, Inc. | 5.87 Million USD | -85.096% |
| Aytu BioPharma, Inc. | 12.63 Million USD | 13.979% |
| SIGA Technologies, Inc. | 64.21 Million USD | 83.078% |
| Tilray Brands, Inc. | 252.08 Million USD | 95.689% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | 72.818% |
| Shineco, Inc. | 1.58 Million USD | -584.094% |
| PetIQ, Inc. | 159.3 Million USD | 93.179% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 7212.935% |
| Incannex Healthcare Limited | -10.01 Million USD | 208.507% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 71.627% |
| Alimera Sciences, Inc. | 1.87 Million USD | -478.34% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | 71.164% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -574.805% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | -142.405% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -4172.426% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | -4.692% |
| Hempacco Co., Inc. | 2.54 Million USD | -327.392% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 85.4% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 77.263% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 83.028% |
| Currenc Group, Inc. | 732.91 Thousand USD | -1382.718% |
| Kamada Ltd. | 87.74 Million USD | 87.615% |
| Indivior PLC | 141.79 Million USD | 92.336% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -2155.313% |
| Flora Growth Corp. | 8.5 Million USD | -27.727% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -4172.426% |
| Evolus, Inc. | 10.99 Million USD | 1.191% |
| HUTCHMED (China) Limited | 50.25 Million USD | 78.378% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 89.732% |
| Akanda Corp. | 1.28 Million USD | -744.436% |